Biomea Fusion (NASDAQ:BMEA – Get Free Report) and Tango Therapeutics (NASDAQ:TNGX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Risk & Volatility
Biomea Fusion has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Institutional & Insider Ownership
96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Comparatively, 6.3% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Biomea Fusion | N/A | -118.90% | -93.66% |
| Tango Therapeutics | -284.42% | -49.64% | -32.00% |
Valuation & Earnings
This table compares Biomea Fusion and Tango Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomea Fusion | N/A | N/A | -$117.25 million | ($3.84) | -0.46 |
| Tango Therapeutics | $42.07 million | 3.62 | -$101.74 million | ($1.21) | -1.17 |
Tango Therapeutics has higher revenue and earnings than Biomea Fusion. Tango Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Biomea Fusion and Tango Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomea Fusion | 0 | 2 | 9 | 2 | 3.00 |
| Tango Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Biomea Fusion currently has a consensus price target of $23.91, suggesting a potential upside of 1,266.23%. Tango Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 774.70%. Given Biomea Fusion’s higher probable upside, equities analysts clearly believe Biomea Fusion is more favorable than Tango Therapeutics.
Summary
Biomea Fusion beats Tango Therapeutics on 7 of the 13 factors compared between the two stocks.
About Biomea Fusion
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
About Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
